Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 9/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 9/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 9/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 9/20 | 0.38 |
| ▸ | PRKAG3 | Q9UGI9 | 9/20 | 0.38 |
| ▸ | PRKAG2 | Q9UGJ0 | 9/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 9/20 | 0.38 |
| ▸ | F10 | P00742 | 8/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | MDH2 | P40926 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27591616 | 0.74 | HPGD (0.51) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL2807531 | 0.70 | MC4R (0.41) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL30166609 | 0.70 | PRKAB2 (0.49) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL2806939 | 0.70 | PRKAB2 (0.49) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL2808561 | 0.70 | SLC22A12 (0.42) | PTGER4 | |
| SCHEMBL31369839 | 0.69 | SLC7A5 (0.50) | — | |
| SCHEMBL16040906 | 0.68 | ADRB2 (0.44) | — | |
| SCHEMBL18508853 | 0.67 | KIF11 (0.47) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL27774896 | 0.66 | GPR84 (0.41) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL5913507 | 0.66 | MAOA (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | PRKAB2 4083/4885PRKAG1 4397/4885PRKAA2 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.